Takashi Masuko

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3549519/publications.pdf

Version: 2024-02-01

83	3,094	279487	161609
papers	citations	23 h-index	54 g-index

88	88	88	4210
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain. Science Translational Medicine, 2022, 14, eaax7706.	5.8	10
2	In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized 64Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility Study. International Journal of Molecular Sciences, 2022, 23, 5807.	1.8	1
3	Antitumor effects of novel mAbs against cationic amino acid transporter 1 (CAT1) on human CRC with amplified CAT1 gene. Cancer Science, 2021, 112, 563-574.	1.7	14
4	Oncogenic transformation of NIH/3T3 cells by the overexpression of L-type amino acid transporter 1, a promising anti-cancer target. Oncotarget, 2021, 12, 1256-1270.	0.8	8
5	Altered binding avidities and improved growth inhibitory effects of novel anti-HER3 mAb against human cancers in the presence of HER1-or HER2-targeted drugs. Biochemical and Biophysical Research Communications, 2021, 576, 59-65.	1.0	2
6	Antiâ€tumor effects of an antagonistic mAb against the ASCT2 amino acid transporter on KRASâ€mutated human colorectal cancer cells. Cancer Medicine, 2020, 9, 302-312.	1.3	25
7	Novel functional anti-HER3 monoclonal antibodies with potent anti-cancer effects on various human epithelial cancers. Oncotarget, 2020, 11, 31-45.	0.8	11
8	Glutaminolysisâ€related genes determine sensitivity to xCTâ€targeted therapy in head and neck squamous cell carcinoma. Cancer Science, 2019, 110, 3453-3463.	1.7	45
9	Antiâ€tumor effects of mAb against <scp>l</scp>â€type amino acid transporter 1 (<scp>LAT</scp>1) bound to human and monkey <scp>LAT</scp>1 with dual avidity modes. Cancer Science, 2019, 110, 674-685.	1.7	24
10	Endothelialâ€“Mesenchymal Transition Drives Expression of CD44 Variant and xCT in Pulmonary Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2019, 61, 367-379.	1.4	27
11	Epigenomic Profiling Discovers Trans-lineage SOX2 Partnerships Driving Tumor Heterogeneity in Lung Squamous Cell Carcinoma. Cancer Research, 2019, 79, 6084-6100.	0.4	24
12	N1-Nonyl-1,4-diaminobutane ameliorates brain infarction size in photochemically induced thrombosis model mice. Neuroscience Letters, 2018, 672, 118-122.	1.0	10
13	Inhibition of tumor formation and metastasis by a monoclonal antibody against lymphatic vessel endothelial hyaluronan receptor 1. Cancer Science, 2018, 109, 3171-3182.	1.7	24
14	Negative regulation of amino acid signaling by MAPK-regulated 4F2hc/Girdin complex. PLoS Biology, 2018, 16, e2005090.	2.6	11
15	Promotion of malignant phenotype after disruption of the three-dimensional structure of cultured spheroids from colorectal cancer. Oncotarget, 2018, 9, 15968-15983.	0.8	15
16	Identification of <scp>ACA</scp>â€28, a 1â€²â€acetoxychavicol acetate analogue compound, as a novel modulator of <scp>ERK MAPK</scp> signaling, which preferentially kills human melanoma cells. Genes To Cells, 2017, 22, 608-618.	0.5	19
17	Saikokaryukotsuboreito during pregnancy protects rat neonates from maternal cannibalism and death in a neurolathyrism experimental model. Traditional & Kampo Medicine, 2016, 3, 107-111.	0.2	0
18	CD44 variantâ€dependent redox status regulation in liver flukeâ€associated cholangiocarcinoma: A target for cholangiocarcinoma treatment. Cancer Science, 2016, 107, 991-1000.	1.7	57

#	Article	IF	Citations
19	The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(â€”). Cancer Research, 2016, 76, 2954-2963.	0.4	84
20	Development of an ErbB4 monoclonal antibody that blocks neuregulin-1-induced ErbB4 activation in cancer cells. Biochemical and Biophysical Research Communications, 2016, 470, 239-244.	1.0	27
21	Immuno-PET Imaging of HER3 in a Model in which HER3 Signaling Plays a Critical Role. PLoS ONE, 2015, 10, e0143076.	1.1	20
22	Identification of antiâ€•CD 98 antibody mimotopes for inducing antibodies with antitumor activity by mimotope immunization. Cancer Science, 2014, 105, 396-401.	1.7	6
23	Functional role of <scp>CD</scp>44vâ€x<scp>CT</scp> system in the development of spasmolytic polypeptideâ€expressing metaplasia. Cancer Science, 2013, 104, 1323-1329.	1.7	78
24	xCT Inhibition Depletes CD44v-Expressing Tumor Cells That Are Resistant to EGFR-Targeted Therapy in Head and Neck Squamous Cell Carcinoma. Cancer Research, 2013, 73, 1855-1866.	0.4	163
25	Imaging the L-Type Amino Acid Transporter-1 (LAT1) with Zr-89 ImmunoPET. PLoS ONE, 2013, 8, e77476.	1.1	31
26	Antagonism of NMDA receptors by butanesulfonyl-homospermine guanidine and neuroprotective effects in in vitro and in vivo. Neuroscience Letters, 2012, 506, 251-255.	1.0	8
27	Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nature Communications, 2012, 3, 883.	5.8	324
28	Anti-Tumor Effect against Human Cancer Xenografts by a Fully Human Monoclonal Antibody to a Variant 8-Epitope of CD44R1 Expressed on Cancer Stem Cells. PLoS ONE, 2012, 7, e29728.	1.1	33
29	<scp>NIH</scp>3<scp>T</scp>3 cells overexpressing <scp>CD</scp>98 heavy chain resist early <scp>G</scp>1 arrest and apoptosis induced by serum starvation. Cancer Science, 2012, 103, 1460-1466.	1.7	9
30	Oncogenicity of L-type amino-acid transporter 1 (LAT1) revealed by targeted gene disruption in chicken DT40 cells: LAT1 is a promising molecular target for human cancer therapy. Biochemical and Biophysical Research Communications, 2011, 406, 649-655.	1.0	31
31	Towards therapeutic antibodies to membrane oncoproteins by a robust strategy using rats immunized with transfectants expressing target molecules fused to green fluorescent protein. Cancer Science, 2011, 102, 25-35.	1.7	20
32	CD44 Variant Regulates Redox Status in Cancer Cells by Stabilizing the xCT Subunit of System xcâ^’ and Thereby Promotes Tumor Growth. Cancer Cell, 2011, 19, 387-400.	7.7	1,020
33	Synthesis of Water-Soluble Polyamine Derivatives Effective as N-Methyl-D-aspartate Receptor Antagonists. Chemical and Pharmaceutical Bulletin, 2010, 58, 862-867.	0.6	3
34	CD44⁺ slowâ€cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E₂ in gastric tumorigenesis. Cancer Science, 2010, 101, 673-678.	1.7	130
35	Significance of integrin Î±vÎ²5 and erbB3 in enhanced cell migration and liver metastasis of colon carcinomas stimulated by hepatocyteâ€derived heregulin. Cancer Science, 2010, 101, 2011-2018.	1.7	34
36	The Cell Surface Protein Geneecm33+Is a Target of the Two Transcription Factors Atf1 and Mbx1 and Negatively Regulates Pmk1 MAPK Cell Integrity Signaling in Fission Yeast. Molecular Biology of the Cell, 2010, 21, 674-685.	0.9	32

#	Article	IF	Citations
37	Neuroprotection by Tosyl-Polyamine Derivatives through the Inhibition of Ionotropic Glutamate Receptors. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 522-530.	1.3	6
38	Antibody epitope peptides as potential inducers of IgG antibodies against CD98 oncoprotein. Cancer Science, 2009, 100, 126-131.	1.7	10
39	Synthesis of a Novel Water-Soluble Cleft-Type Cyclophane as an N-Methyl-D-aspartate Receptor Antagonist. Chemical and Pharmaceutical Bulletin, 2009, 57, 95-98.	0.6	1
40	Synthesis of a novel waterâ€soluble NMDA receptor antagonist. Journal of Heterocyclic Chemistry, 2008, 45, 383-387.	1.4	3
41	Cellâ€deathâ€inducing monoclonal antibodies raised against DT40 tumor cells: Identification of chicken transferrin receptor as a novel cellâ€death receptor. Cancer Science, 2008, 99, 894-900.	1.7	9
42	Production and characterization of highly tumor-specific rat monoclonal antibodies recognizing the extracellular domain of human l-type amino-acid transporter 1. Cancer Science, 2008, 99, 1000-1007.	1.7	30
43	Differential effects of linear and cyclic polyamines on NMDA receptor activities. Neurochemistry International, 2008, 53, 38-44.	1.9	2
44	Simultaneous induction of apoptotic, autophagic, and necrosis-like cell death by monoclonal antibodies recognizing chicken transferrin receptor. Biochemical and Biophysical Research Communications, 2008, 367, 775-781.	1.0	7
45	Cleft-type cyclophanes confer neuroprotection against excitatory neurotoxicity in vitro and in vivo through inhibition of NMDA receptors. Neuropharmacology, 2007, 53, 515-523.	2.0	6
46	Cyclophane and acyclic cyclophane: Novel channel blockers of N-methyl-d-aspartate receptor. Neurochemistry International, 2007, 50, 443-449.	1.9	11
47	Identification of cell proliferation-associated epitope on CD98 oncoprotein using phage display random peptide library. Cancer Science, 2007, 98, 1696-1700.	1.7	8
48	Design and Synthesis of a Novel Water-Soluble NMDA Receptor Antagonist with a 1,4,7,10-Tetraazacyclododecane Group. Chemical and Pharmaceutical Bulletin, 2005, 53, 444-447.	0.6	8
49	Monoamines directly inhibit N-methyl-d-aspartate receptors expressed in Xenopus oocytes in a voltage-dependent manner. Neuroscience Letters, 2004, 371, 30-33.	1.0	22
50	Molecular Structural and Functional Characterization of Tumor Suppressive Anti-ErbB-2 Monoclonal Antibody by Phage Display System. Journal of Biochemistry, 2003, 133, 239-245.	0.9	11
51	Immunohistochemical expression and pathogenesis ofBLMin the human brain and visceral organs. Neuropathology, 2001, 21, 123-128.	0.7	5
52	Monoclonal antibody (5F3) defining renal cell carcinoma-associated antigen disialosyl globopentaosylceramide (V3NeuAcIV6NeuAcGb5), and distribution pattern of the antigen in tumor and normal tissues. Glycoconjugate Journal, 2001, 18, 475-485.	1.4	23
53	In vivo evidence that protease-activated receptors 1 and 2 modulate gastrointestinal transit in the mouse. British Journal of Pharmacology, 2001, 133, 1213-1218.	2.7	71
54	Phage Display Cloning and Characterization of Monoclonal Antibody Genes and Recombinant Fab Fragment against the CD98 Oncoprotein. Japanese Journal of Cancer Research, 2001, 92, 1313-1321.	1.7	15

#	Article	IF	Citations
55	Transformation of BALB3T3 cells caused by over-expression of rat CD98 heavy chain (HC) requires its association with light chain: Mis-sense mutation in a cysteine residue of CD98HC eliminates its transforming activity. International Journal of Cancer, 2000, 87, 311-316.	2.3	43
56	Enhanced tumorigenicity caused by truncation of the extracellular domain of GP125/CD98 heavy chain. Oncogene, 2000, 19, 6209-6215.	2.6	26
57	Malignant Transformation of NIH3T3 Cells by Overexpression of Early Lymphocyte Activation Antigen CD98. Biochemical and Biophysical Research Communications, 1999, 262, 720-725.	1.0	63
58	Identification of Truncated Human Glutamate Transporter.. Tohoku Journal of Experimental Medicine, 1999, 187, 173-182.	0.5	10
59	Identification and Immunological Characterization of a Novel 40-kDa Protein Linked to CD98 Antigen.. Cell Structure and Function, 1999, 24, 217-226.	0.5	2
60	Homotypic Adhesion through Carcinoembryonic Antigen Plays a Role in Hepatic Metastasis Development. Japanese Journal of Cancer Research, 1998, 89, 177-185.	1.7	28
61	Binding of Serum Albumin on Tumor Cells and Characterization of the Albumin Binding Protein. Journal of Biochemistry, 1994, 115, 898-903.	0.9	24
62	Pre-Kupffer Like CD4/CD8 Double Positive Mononuclear Cells Present in Rat Liver. Journal of Biochemistry, 1994, 115, 904-908.	0.9	3
63	Derivation and Application of Monoclonal Antibodies Recognizing Several Epitopes on Bovine Serum Albumin.. Tohoku Journal of Experimental Medicine, 1994, 172, 345-353.	0.5	5
64	Specific targeting of in vitroâ€activated human antitumour effector cells using antiâ€CD3 Ã— antiâ€câ€erbBâ€2 bispecific antibody. Immunology and Cell Biology, 1993, 71, 109-115.	1.0	6
65	Intracellular Localization of UDP-Glucuronosyltransferase Expressed from the Transfected cDNA in Cultured Cells.. Cell Structure and Function, 1993, 18, 41-51.	0.5	11
66	HumanC-ERBB-2 proto-oncogene product as a target for bispecific-antibody-directed adoptive tumor immunotherapy. International Journal of Cancer, 1992, 50, 800-804.	2.3	30
67	Release of Esterase from Murine Lymphokine-activated Killer Cells in Antibody-dependent Cellular Cytotoxic Reaction. Japanese Journal of Cancer Research, 1991, 82, 206-212.	1.7	6
68	Increase in Colony Stimulating Factor(CSF) in serum and augmentation of CSF responsiveness of lymphoid mononuclear cells by acute Trypanosoma cruzi infection in mice.. Tohoku Journal of Experimental Medicine, 1990, 160, 67-79.	0.5	1
69	Immunohistochemical Analysis of câ€erbBâ€2 Oncogene Product and Epidermal Growth Factor Receptor Expression in Human Urinary Bladder Carcinomas. Pathology International, 1990, 40, 322-326.	0.6	5
70	A tumor-associated antigen in the scirrhous gastric carcinoma cell line MK-01 defined by monoclonal antibody S202. The Japanese Journal of Surgery, 1989, 19, 452-458.	0.2	1
71	Increase in murine monoclonal-antibody-defined urinary antigens in patients with bladder cancer and benign urogenital disease. International Journal of Cancer, 1989, 44, 582-588.	2.3	5
72	A Murine Monoclonal Antibody that Recognizes an Extracellular Domain of the Human c-erbB-2 Protooncogene Product. Japanese Journal of Cancer Research, 1989, 80, 10-14.	1.7	47

#	Article	IF	Citations
73	Strain Differences in Susceptibility to 2-Acetylaminofluorene and Phenobarbital Promotion of Hepatocarcinogenesis: Immunohistocliemical Analysis of Cytochrome P-450 Isozyme Induction by 2-Acetylaminofluorene and Phenobarbital. Japanese Journal of Cancer Research, 1989, 80, 1041-1046.	1.7	18
74	Changes in the Quantity and Activity of Cytochrome P-450 Isozymes in Primary Cultured Rat Hepatocytes. Japanese Journal of Cancer Research, 1989, 80, 126-131.	1.7	5
75	In vitroTargeting and Cytotoxicity of Adriamycin in Liposomes Bearing Monoclonal Antibody against Rat or Human gp125 Cell Proliferation-associated Antigen. Japanese Journal of Cancer Research, 1989, 80, 380-386.	1.7	14
76	Scirrhous carcinoma cell invasion into the stomach wall detected by monoclonal antibody S202: A comparison between immunoperoxidase and hematoxylin-eosin stain.. Tohoku Journal of Experimental Medicine, 1989, 157, 137-144.	0.5	1
77	Production and characterization of monoclonal antibodies against trypanosoma cruzi-associated antigens.. Tohoku Journal of Experimental Medicine, 1989, 159, 313-321.	0.5	5
78	A microtestplate-immunofluorescence assay for anti-Trypanosoma cruzi antibodies.. Tohoku Journal of Experimental Medicine, 1989, 159, 307-312.	0.5	3
79	Localization of antigen defined by anti-scirrhous gastric carcinoma monoclonal antibody S202 in fixed human cancer tissues. Gastroenterologia Japonica, 1988, 23, 619-623.	0.4	2
80	Appearance of a Proliferation-Associated Antigen, gp125, on Rat and Human Lymphocytes by Co-Stimulation with Phorbol Ester and Calcium Ionophore1. Journal of Biochemistry, 1988, 103, 644-649.	0.9	10
81	Organ Selective Induction of Cytochrome P-448 Isozymes in the Rat by 2-Methoxy-4-Aminoazobenzene and 3-Methylcholanthrene1. Journal of Biochemistry, 1987, 101, 1437-1445.	0.9	20
82	A monoclonal antibody against human colon cancers.. Tohoku Journal of Experimental Medicine, 1986, 148, 353-360.	0.5	67
83	Cell Surface Antigens in Normal and Neoplastic Urinary Bladder Epithelial Cells of the Rat<xref ref-type="fn" rid="FN2">2</xref>. Journal of the National Cancer Institute, 1981, , .	3.0	2